{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6sq4oJDA","lastupdate":"2022-11-21T00:00:00.000Z","update_date":"2022-11-21T00:00:00.000Z","lastModified":"Feb 17, 2025","active":1,"confidence_score":92,"confidence_score_reason":"markets, not claimed","urlname":"eyeyon","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$i7qTnXujDHBFlWqOeU7FOBD1hNA4rhtNw6FLVjIMgJdr9rbbtJUquZ","name":"EyeYon Medical","oneliner":"Ophthalmic Products for Vision-threatening Conditions","registrar":"514509603","website":"https://eye-yon.com","careerspage":"","founded_month":1,"founded_year":2010,"formernames":[],"sociallinks":{"twitter":"https://twitter.com/EyeyonM","youtube":"https://www.youtube.com/channel/UCDOTw_YQzvPA5fnOzU2004g","facebook":"https://www.facebook.com/EyeYon","linkedin":"https://www.linkedin.com/company/2287913","instagram":""},"social":["https://www.youtube.com/channel/UCDOTw_YQzvPA5fnOzU2004g","https://www.facebook.com/EyeYon","https://twitter.com/EyeyonM","https://www.linkedin.com/company/2287913"],"flattenedsociallinks":"https://www.youtube.com/channel/UCDOTw_YQzvPA5fnOzU2004g|https://www.facebook.com/EyeYon|https://twitter.com/EyeyonM|https://www.linkedin.com/company/2287913","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"11-50","employees_exact":30,"patent":1,"raised":36138000,"stage":"C","public_stage":"C","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Eye Yon","Eye.Yon","Eyeon","Eye-Yon"],"about":"EyeYon Medical is a start-up company specializing in developing medical ophthalmic devices for complications resulting from various corneal diseases, including corneal edema. EyeYon Medical has developed exclusive technologies that have proven to have a solution to acute problems in the ophthalmic world.\n\nEyeYon Medical's flagship product is an artificial endothelial layer called EndoArt. EndoArt is a synthetic implant attached to the posterior corneal surface to treat chronic corneal edema secondary to endothelial dysfunction. The minimally invasive EndoArt is designed to replace dysfunctional endothelium to cure corneal edema, offering a safe and simple solution that will be available to anyone, anywhere.\n\nEyeYon Medical also developed the Hyper CL, an FDA-approved therapeutic contact lens for a variety of corneal conditions that require eye drop treatment.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+972737803607","country":null,"address":{"israeli":[{"id":"fbf8f9e9-7856-4c0d-9acf-8b1d887ea4d0","city":"Ness Ziona","type":null,"address":"5 Golda Meir St., Ness Ziona, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"FA86xICHjuNQGdah6QLvc90dDIrCm4DFtCeIgHxBqAz7O2zjTngqQb","date":"Feb 5, 2025","link":"https://www.prnewswire.com/il/news-releases/eyeyon-medical-expands-into-china-with-new-subsidiary-302367583.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"expansion","round":null,"company":"EyeYon Medical","layoffs":null,"summary":"EyeYon Medical has announced its expansion into China with the establishment of a new subsidiary, Zhuhai EyeYon Medical Technology Co., Ltd. This strategic move aims to address unmet needs in Chinas ophthalmology sector, particularly focusing on corneal blindness. The expansion is expected to accelerate EyeYons growth trajectory by allowing the company to better serve Chinese patients and healthcare providers. The subsidiary will focus on product localization, strategic partnerships, clinical studies, regulatory compliance, and talent acquisition. EyeYon Medical is committed to integrating its technologies into the Chinese healthcare system and supporting local communities through educational and philanthropic activities. The companys EndoArt, a synthetic corneal implant, is highlighted as a groundbreaking alternative to donor tissue.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["China expansion","corneal blindness","EndoArt implant","regulatory compliance","strategic partnerships"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Expand","Partners","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Expand  #Partners  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"q9Syt1OTvRc1IiksI7RrKOManLgHXJmlYRa1OELHSPV6DVXSvVV60A","news_summary":"/PRNewswire/ -- EyeYon Medical is proud to announce its expansion in China with the establishment of a new subsidiary, Zhuhai EyeYon Medical Technology Co.,...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"lzyA1Epaybg80yPEa11iVMffYlpqdDfV24R5QvyPsdMflyHoPsf785","date":"Feb 22, 2022","link":"https://www.prnewswire.com/il/news-releases/eyeyon-medical-appoints-dr-sharon-bakalash-md-phd-as-chief-medical-officer-838429910.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"appointment","company":"EyeYon Medical","layoffs":null,"summary":"EyeYon Medical announces the appointment of Dr. Sharon Bakalash as Chief Medical Officer. Dr. Bakalash brings extensive experience in clinical development and medical affairs to the company. She will lead the clinical activity for EyeYon Medicals innovative products, including the EndoArt synthetic corneal endothelium and the HyperCL contact lens. The CEO of EyeYon Medical, Nahum Ferera, expresses his excitement about having Dr. Bakalash as a leader for the companys global clinical activity. Dr. Bakalash has a strong background in the ophthalmic space, having worked with biotechnology companies and served as a chief medical officer in the industry. She holds an MD, a PhD, and a business degree.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Dr. Sharon Bakalash","Chief Medical Officer","EndoArt","HyperCL","ophthalmic medical devices"],"date_of_event":"2022-02-22","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"qQcXQ04oX05SLUZwFNNfrX2W58hk0MeNyUklDGTbYTGrmglHI8w20I","news_summary":"EyeYon Medical Appoints Dr. Sharon Bakalash MD, PhD As Chief Medical Officer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"H6dHj4KbqLxHXdADLccMKSfH2TVxeK599fPGEnBljBCrpb8ksf5w9Z","date":"Jun 7, 2021","link":"https://nocamels.com/2021/06/eyeyon-medical-endoart-implant-cornea/","source":"nocamels.com","visible":1,"analysis":{"tags":"medical technology","company":"EyeYon Medical","layoffs":null,"summary":"Israeli startup EyeYon Medical has received a CE Mark for its EndoArt implant, a synthetic implant that replaces the human endothelium to treat chronic corneal edema. The implant eliminates the need for corneal donations and offers a minimally invasive surgery option. EyeYon Medical has also raised $25 million, bringing its total capital raised to $36 million. The company plans to work closely with healthcare providers in Europe to provide the innovative solution to patients suffering from corneal edema.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["CE Mark","EndoArt implant","corneal edema","clinical trials","synthetic implant"],"date_of_event":"2021-03-01","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$25 million","structured_issues":["Customers","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"5CE3TDKh0tCW0HRUtx24WWX637jm3Bqx1NnNxwYiav7d7uitSmDGO0","news_summary":"Israel's EyeYon Medical Receives CE Mark For Its Synthetic Implant","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a36c2f9b-9a67-4028-acd0-6ba880a700bc","date":"Apr 7, 2021","link":"https://www.prnewswire.com/il/news-releases/eyeyon-medical-announces-innovative-medical-device-designation-granted-for-endoart-r-in-china-867935671.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"medical devices","company":"EyeYon Medical","layoffs":null,"summary":"EyeYon Medicals EndoArt® has been granted the Innovative Device Status by Chinas Center for Medical Device Evaluation. It is the only ophthalmic device in the world to receive both Chinas Innovative Device Status and the Breakthrough Device Designation from the U.S. FDA. EndoArt® is a synthetic implant that treats chronic corneal edema, reducing the need for human donor tissue. The company has conducted clinical trials in Europe, India, and Israel, showing significant reduction in edema. EyeYon Medical plans to begin its first in-human trial in China soon. The companys investors, including Rimonci Capital, are supporting its technology advancement in China.","partners":"Rimonci Capital","customers":null,"investors":"Rimonci Capital","confidence":8,"key_topics":["EndoArt®","ophthalmic products","Chinas Innovative Device Status","Breakthrough Device Designation","corneal edema"],"date_of_event":"April 7, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"qDomiHrMEfzkg4iihsbQE1sapKEhEN5SPuk4tJiCsnmC2jhPcFecdt","news_summary":"EyeYon Medical Announces Innovative Medical Device Designation Granted For EndoArt® In China","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"fc5cf06b-1f98-4f25-b032-eba9fa9b0f70","date":"Mar 15, 2021","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3899001,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"medical technology","company":"EyeYon Medical","layoffs":null,"summary":"Israeli life sciences company EyeYon Medical has raised $25 million in a series C investment round. The funds will be used to expand the clinical trials of its flagship product, the EndoArt, a synthetic implant that treats chronic corneal edema. The implant eliminates the need for human tissue or corneal donations. EyeYon Medical aims to simplify corneal surgical procedures and address the long waiting list for available human donor corneas. The companys technology has already shown safety and efficacy in human trials. The funding round reflects investor confidence in the companys unique and disruptive technology.","partners":null,"customers":null,"investors":"global strategic leader in the ophthalmic industry, CR-CP Life Science Fund, Global Health Sciences (GHS) Fund, BPC, Triventures, Rimonci, Pontifax, Diamond BioFund","confidence":9,"key_topics":["synthetic implant","corneal edema","investment","clinical trials","expansion"],"date_of_event":"2021-03-15","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$25 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UqjDvArgKZOTqGyh92TDLdAhAeWtwdNIa5aIkefNX0rwuFVkBcN1Ws","news_summary":"EyeYon Medical raises $25 million for corneal implants","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"beddf60d-149b-4205-99f8-4799f86403c3","date":"Sep 24, 2020","link":"https://www.maariv.co.il/business/tech/Article-791829","source":"www.maariv.co.il","visible":1,"analysis":{"tags":"medical technology","company":"EyeYon Medical","layoffs":null,"summary":"Israeli startup EyeYon Medical has developed an artificial eye implant to address the long waiting times for corneal transplantation surgeries. The company aims to provide a safe and simple solution that will be available to everyone. The implant, called EndoArt, replaces the damaged layer of the cornea and has shown promising results in human trials. EyeYon Medical plans to expand its clinical trials and seek regulatory approval in Europe and the US. The company is based in Nes Ziona Science Park and currently employs ten people. Its goal is to bring about a significant change in the field of corneal transplantation and improve vision for millions of people worldwide.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["artificial eye implant","eye transplantation","medical technology","vision impairment","clinical trials"],"date_of_event":"2020-09-24","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"NkRFTPdegY9ZoCiC2su0x4LBzFtUB0FO4OZHcVDsnkWYUu78pW9AUi","news_summary":"מבט לעתיד: המיזם הישראלי שפיתח שתל מלאכותי לעין","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"337b288a-3548-4d3c-8db4-95524b16bcaa","date":"Feb 5, 2020","link":"https://www.prnewswire.com/news-releases/breakthrough-device-designation-received-from-the-fda-for-endoart-300999343.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"medical device","company":"EyeYon Medical","layoffs":null,"summary":"EyeYon Medical, a start-up company developing ophthalmic products, has received Breakthrough Device Designation from the FDA for its Artificial Endothelial Layer implant called EndoArt®. The implant is designed to treat chronic corneal edema secondary to endothelial dysfunction. It aims to replace dysfunctional endothelium in patients where human donor tissue has failed to resolve the edema. The Breakthrough Device Designation will accelerate the development and review process of EndoArt®, providing timely access to the device for patients and healthcare providers. EyeYon Medical aims to improve the quality of life for millions of patients suffering from corneal edema.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["EyeYon Medical","Breakthrough Device","Artificial Endothelial Layer","corneal edema","EndoArt®"],"date_of_event":"2020-02-05","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"DYfEssKRnTWx32Wu9yf2QiUs9QZrv7b7o0h0g7cQJHnZWmdMVjPWeK","news_summary":"Breakthrough Device Designation Received From the FDA for EndoArt®","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"fabbccd8-5960-4d0f-9a9b-e47ecd49ce9a","date":"Mar 21, 2017","link":"http://www.globes.co.il/en/article-ophthalmic-device-co-eyeyon-medical-raises-65m-1001181829","source":"www.globes.co.il","visible":1,"analysis":{"tags":"Investment, Expansion","company":"EyeYon Medical","layoffs":"Not mentioned","summary":"Israeli ophthalmic device company EyeYon Medical has raised $6.5m in a funding round led by China-based venture capital fund Rimonci Capital and co-investor Gauss Group. Existing investors Triventures and Pontifax also participated in the round, along with a grant from Israels Chief Scientist. EyeYon Medical, which specialises in medical ophthalmic devices, plans to use the funding to expand its product platform, complete the EndoArt first in human safety and performance study, obtain regulatory approval for EndoArt, continue Hyper CL development for additional indications as a drug delivery platform and grow sales and marketing activities globally.","partners":"Rimonci Capital","customers":"Not mentioned","investors":["Rimonci Capital","Gauss Group","Triventures","Pontifax"],"confidence":9,"key_topics":["Venture Capital","Ophthalmic Devices"],"date_of_event":"March 21, 2017","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$6.5 million","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ZvawGkQkUFiV76cRo6j2ksI6bpHkpmKcmybG8w7z78DPg7jK8WozAn","news_summary":"Ophthalmic device co EyeYon Medical raises $6.5m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"09295b11-2c3f-40e6-8c95-ed51a0e1bae4","date":"Sep 6, 2016","link":"https://blog.optoprep.com/link-fda-approves-eyeyon-corneal-edema-treatment","source":"blog.optoprep.com","visible":1,"analysis":{"tags":"medical contact lens","company":"EyeYon","layoffs":null,"summary":"EyeYon, an Israeli company, has received US marketing authorization for its medical contact lens, Hyper-CL, used for the treatment of corneal edema. The lens is designed with a reservoir that allows hypertonic drops to have a longer contact time with the cornea, improving the extraction of excess fluids. The product is commercially available in Europe and will soon be available in the US. It can be prescribed for daily wear and can also provide optical correction during the healing process. The technology also has potential for medication delivery for other ocular conditions.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["medical contact lens","corneal edema","US marketing authorization","Hyper-CL","therapeutic use"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ucujopwZqMAjuk26a6FHmdODzlwPfSLj620oGKaohID3mgeVQ2Du7Z","news_summary":"Link: FDA Approves EyeYon Corneal Edema Treatment","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b006bbc7-3e08-443c-a2fd-1430dd37864e","date":"Apr 21, 2015","link":"https://en.globes.co.il/en/article-israeli-eye-treatment-co-eyeyon-medical-raises-36-1001030045","source":"en.globes.co.il","visible":1,"analysis":{"tags":"medical device","company":"EyeYon Medical","layoffs":null,"summary":"Israeli medical device start-up EyeYon Medical has raised $3.6 million in funding. The funds will be used to develop the companys corneal edema treatment products. EyeYon Medicals leading product is a hyper-osmotic contact lens that absorbs corneal fluids and alleviates symptoms. The company also has another product in development that aims to cure the disease entirely. The investment will be used for additional clinical trials, global market penetration, and product development.","partners":null,"customers":null,"investors":["Pontifax","TriVentures","Office of the Chief Scientist","Docor International"],"confidence":9,"key_topics":["corneal edema","investment","product development","clinical trials","global markets"],"date_of_event":"April 21, 2015","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$3.6 million","structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"QN8ugQovBEl6sC8JZV6feo7rEJyzNPO9qqh3WI8cwUIL9DWiyXKEGg","news_summary":"Israeli eye treatment co EyeYon Medical raises $3.6m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f5c2eb91-150c-4a94-9337-04de73a44a98","date":"Feb 25, 2014","link":"http://blogs.timesofisrael.com/trailblazing-is-israels-last-name/","source":"blogs.timesofisrael.com","visible":1,"analysis":{"tags":"medical technology","company":"EyeYon Medical","layoffs":null,"summary":"EyeYon Medical, a medical technology company based in Jerusalem, has developed an innovative contact lens treatment for eye diseases, particularly corneal edema. The treatment, which consists of a disposable contact lens that acts as a pump to extract fluids from the cornea, has passed clinical testing in Israel and received CE approval to market in Europe. The company is also working on a hydrophobic implant to prevent corneal edema and eliminate the need for corneal transplants. The article highlights the technological innovation and potential impact of EyeYon Medicals treatment on improving the quality of life for patients with corneal edema.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["technology","eye diseases","corneal edema","contact lens","non-surgical treatment"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"enLJeHC0FChBrgQfQUaB9EWvzQ2NVJ4vWmUTM9wOy7aHhSo3cEnIxA","news_summary":"Trailblazing is Israel's last name","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"67787eb5-2511-4069-846a-2786ae002837","date":"Aug 1, 2013","link":"http://www.israel21c.org/eyeyons-noninvasive-answer-to-a-common-eye-problem/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"therapeutic contact lens","company":"EyeYon Medical","layoffs":null,"summary":"Israeli startup EyeYon Medical has developed a patented therapeutic contact lens, Hyper CL, to relieve symptoms of corneal edema. The lens extracts fluids by osmosis and smooths the surface of the cornea, improving vision and protecting from infection. The Hyper CL has already received the European CE Mark and is expected to enter the market in 2014. EyeYon is also developing a silicon film implant, DSPEK, to prevent corneal edema during or after cataract and transplant surgery. The potential market for EyeYons products is estimated to be worth $500 million worldwide. The company is currently financed by various investors and is chaired by Elka Nir.","partners":null,"customers":null,"investors":"Office of Chief Scientist, Docor, Jerusalem Development Authority, Sagam Versano","confidence":8,"key_topics":["corneal edema","therapeutic contact lens","clinical trials","DSPEK","market potential"],"date_of_event":"2013","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"eO0PcBFlRMe5hlyAJwnRxHpTVSc92Ps4FZXZfZa7t1gauHX0RtlD6K","news_summary":"EyeYon's noninvasive answer to a common eye problem","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":12,"techcommunityinvolvement":null,"mediagallery":[{"id":"3213c16f-7a8d-44b0-853b-f9a6e4c19481","timestamp":"2021-03-16 10:34:59.000000","resources_type":1,"resources_title":"HyperCL","resources_file_name":"$lTtxu8Fivp9H2qNTCBVlLCnh9pqXp2PGIjdLwMFDlPboQI4GfheCyL","alt":"HyperCL logo","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$lTtxu8Fivp9H2qNTCBVlLCnh9pqXp2PGIjdLwMFDlPboQI4GfheCyL","url":"https://storage.googleapis.com/clean-finder-353810/$lTtxu8Fivp9H2qNTCBVlLCnh9pqXp2PGIjdLwMFDlPboQI4GfheCyL"},{"id":"8f1c1350-bf25-4138-9ee4-29dd1a41e017","timestamp":"2020-07-22 10:55:46.000000","resources_type":2,"resources_title":"Eyeon1","resources_file_name":"caHuG7CqL7Y","alt":"Eyeon1 logo","imageurl":"https://img.youtube.com/vi/caHuG7CqL7Y/0.jpg","url":"http://youtu.be/caHuG7CqL7Y"},{"id":"7cba68e3-b33c-4220-b3a1-67eb77ce89f9","timestamp":"2018-07-26 07:17:37.000000","resources_type":2,"resources_title":"Demo","resources_file_name":"oKvQdLoPxyo","alt":"Demo logo","imageurl":"https://img.youtube.com/vi/oKvQdLoPxyo/0.jpg","url":"http://youtu.be/oKvQdLoPxyo"},{"id":"2aab6848-63a6-4e37-950a-35139f46f362","timestamp":"2017-12-21 13:08:48.000000","resources_type":2,"resources_title":"","resources_file_name":"xp97oDyfg0g","alt":"","imageurl":"https://img.youtube.com/vi/xp97oDyfg0g/0.jpg","url":"http://youtu.be/xp97oDyfg0g"}],"tags":["bioconvergence","medical-technologies","eye-diseases","medical-devices","minimally-invasive","ophthalmology","patients","lenses","non-invasive","non-surgical","clinics","healthcare-providers","hospitals","treatments","optronics"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeKhcYLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":[{"date":"2010-10-01","name":"Ophthalmic devices for Corneal Edema Treatment","tags":["lenses","ophthalmology","eye-diseases","minimally-invasive"],"category":"Medical Devices","tto_logo":"/image_cloud/mor-research-applications_tto_logo_ebbdad70-6016-11e8-a05b-41fdcbb0dda6","university_logo":"/image_cloud/mor-research-applications_institution_logo_ebbdad70-6016-11e8-a05b-41fdcbb0dda6"},{"date":"2016-08-18","name":"Hyper-osmotic eye contact lens","tags":["medical-products"],"category":"Medical Devices","tto_logo":"/image_cloud/mor-research-applications_tto_logo_ebbdad70-6016-11e8-a05b-41fdcbb0dda6","university_logo":"/image_cloud/mor-research-applications_institution_logo_ebbdad70-6016-11e8-a05b-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2B"],"productstage":"Released","products":["EndoArt","Hyper-CL"],"geomarkets":["United States","Europe","India","China"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":12,"lastfunding":"$25M","totalrounds":4,"fundingstage":"C","totalfunding":"$36.14M","publicinvestors":12,"lastpublicfunding":25000000,"totalpublicrounds":4,"totalpublicfunding":36138000},"team":[{"name":"Nahum  Ferera","email":"nahum@eye-yon.com","phone":"0543023333","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwMTVwYAKDA","bounced":false,"claimed":0,"founder":1,"urlname":"nahum-ferera","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDAxPHAkQoM","position":"Co-founder & CEO","last_name":"Ferera","claimtoken":"20wX7bgLnyuYc1anq5AjThw0XqMKzFCXTG7XzeNKKcMcUvlyPghYAA","first_name":"Nahum ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/nahum-ferera-48273810/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-11-21 14:15:47.000000","initials":"NF","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Arie Marcovich","email":"arie@eye-yon.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4NudjvEKDA","bounced":true,"claimed":0,"founder":1,"urlname":"arie-marcovich","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgu_PZmgkM","position":"Co-founder ","last_name":"Marcovich","claimtoken":"8vR8WXxoyF1FYsgh6G0AOhn0pmotg9fWQ5wWdrk6ZCfLDPXcC6gWca","first_name":"Arie","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/arie-marcovich-79b235109/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-11-21 14:16:04.000000","initials":"AM","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Ofer  Daphna","email":"ofer@eye-yon.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoLqrvNYIDA","bounced":false,"claimed":0,"founder":1,"urlname":"ofer-daphna-2","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgipzC2QkM","position":"Co-founder & Medical Director","last_name":"Daphna","claimtoken":"a901a08470648788142cc74336817bbffca811a39e5a09354dc4a79807a6a39a","first_name":"Ofer ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/ofer-daphnah-3bba6339/","unsubscribed":false,"is_activeuser":1,"additionalemail":"odaphna@gmail.com","claimedemaildate":"2020-12-09 12:00:23.000000","initials":"OD","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Sharon  Bakalash","email":"sharon@eye-yon.com","phone":"","gender":"Female","userid":"cfgoneeoDDUzcRWjCel9C0TXCqQ2J5sLFuTv5icrNkKSi2wWRJZF00","bounced":false,"claimed":null,"founder":0,"urlname":"sharon-bakalash","visible":1,"memberid":"84gy7p1hn7avW7v96ibq4HMnW5cinuoEHGUgNMw4sPz5QxTRLygzfH","position":"CMO","last_name":"Bakalash","claimtoken":"yAGueBkc5BzxsblhwXm10dvCGAm4kHkkL9e3ebDL4cdplJoGPqCDyJ","first_name":"Sharon ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/sharonbakalash/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-11-21 14:35:40.000000","initials":"SB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Dmitry  Dubson","email":"dmitry@eye-yon.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoLqtiJgLDA","bounced":false,"claimed":0,"founder":0,"urlname":"dmitry-dubson","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgm-ix2gsM","position":"VP R&D","last_name":"Dubson","claimtoken":"ZDUjbo0QJQFEOUd8oESRTZRfUOXReTdlrDsd1pconB9FnP7av7SEMI","first_name":"Dmitry ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/dmitry-dubson-b274204/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-11-21 14:16:23.000000","initials":"DD","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwPi8kYoKDA","fullname":"Ayelet Beazley"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-03-10T00:00:00.000Z","crunchbaseid":"eyeyon","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Rebecca Mack","creator_email":"rebeccamack26@gmail.com","createdate":"2014-07-17T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Ayelet Beazley","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD7wsffCww","date":"Mar 2021","amount":"$25M","source":"https://www.calcalistech.com/ctech/articles/0,7340,L-3899001,00.html","eventtype":"FundingRoundEvent","investment":[{"name":"CR-CP Life Science Fund","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/cr-cp-life-science-fund","logokey":"$WdsFXZ0KSopNYQQT3Blpy40aG53OqLplEalxSZSCZoMggy3vYLKVC7","tagline":"","urlname":"/investor_page/cr-cp-life-science-fund","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCxhMbjCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"34392b68-c7bb-41c2-8383-136d1a1f2859","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$WdsFXZ0KSopNYQQT3Blpy40aG53OqLplEalxSZSCZoMggy3vYLKVC7","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"Triventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/triventures","logokey":"$dzsYbSrKJgvPvZBbbhpoltTv6B2WRBi4fCaQ7HOyP0c9HhBg7OFO8N","tagline":null,"urlname":"/investor_page/triventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJHdj50LDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"25dc8f5b-2e60-4373-86d1-1f25abea012d","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$dzsYbSrKJgvPvZBbbhpoltTv6B2WRBi4fCaQ7HOyP0c9HhBg7OFO8N","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"Quark Venture","type":"Investor","amount":0,"hidden":false,"country":"Canada","fullurl":"/investor_page/quark-venture","logokey":"$YqTloV7jHhFJJgexhl8uKOwKGRlphv3Hg6jIB4VrIT6PyOv9oLRWLH","tagline":"","urlname":"/investor_page/quark-venture","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCUwsWJCAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"2ed1b804-bcad-4bad-be9f-e506cfb4439f","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YqTloV7jHhFJJgexhl8uKOwKGRlphv3Hg6jIB4VrIT6PyOv9oLRWLH","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Diamond Bio Fund ","type":"Investor","amount":0,"hidden":false,"country":"Taiwan","fullurl":"/investor_page/diamond-bio-fund","logokey":"$RBmMZA7Nq3HCX8yiJgcmSVnzy04oqJK6CPrYOcDyWVNod5FRaUtaaM","tagline":"","urlname":"/investor_page/diamond-bio-fund","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODY5ZHzCAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"39f061d4-3959-42c2-982b-7e27624d8349","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$RBmMZA7Nq3HCX8yiJgcmSVnzy04oqJK6CPrYOcDyWVNod5FRaUtaaM","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"BPC","type":"Investor","amount":0,"hidden":false,"country":"Hong Kong","fullurl":"/investor_page/bpc","logokey":"$5LpX3UyIHnSCti51BHS7rHQYLbSUeAxsrE38k2XbGIWXglhasOpkEt","tagline":"","urlname":"/investor_page/bpc","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCb2IaFCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"9b27f373-1d49-4b7f-9708-c5530017a317","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$5LpX3UyIHnSCti51BHS7rHQYLbSUeAxsrE38k2XbGIWXglhasOpkEt","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"c08da446-12fe-4578-a2af-af9061ab76d3","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"Rimonci Capital","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/rimonci-capital-1","logokey":"$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","tagline":"","urlname":"/investor_page/rimonci-capital-1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCRwd68CAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"d342b8bc-0e54-41cb-84c0-9fc1e6729abe","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"C Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":25000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOC4jubUCww","date":"Mar 2017","amount":"$8M","source":"From Yishai Potack, their VP BD","eventtype":"FundingRoundEvent","investment":[{"name":"Rimonci Capital","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/rimonci-capital-1","logokey":"$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","tagline":"","urlname":"/investor_page/rimonci-capital-1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCRwd68CAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"9473bc17-35af-456d-a6a3-cd1ecbb3f912","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","leadcaption":"","followupcaption":""},{"name":"Gauss Group","type":"Company","amount":0,"hidden":true,"country":"United States","fullurl":"/company_page/gauss-group","logokey":"$miV2PdhPZ9qkQhc613cswuVLhYjU9YgAdbyWqNVlXoaevIN5ordyKS","tagline":"Software Development and Data Science Consulting Services","urlname":"/company_page/gauss-group","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEvIy7CQw","fundingtype":"Company","leadpartner":null,"investmentid":"d38f45f6-5f8d-481e-abe9-a064dcf1b6ec","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$miV2PdhPZ9qkQhc613cswuVLhYjU9YgAdbyWqNVlXoaevIN5ordyKS","leadcaption":"","followupcaption":""},{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"ed858b52-091a-403e-a4ef-469e47188221","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"","followupcaption":"Follow on "},{"name":"Triventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/triventures","logokey":"$dzsYbSrKJgvPvZBbbhpoltTv6B2WRBi4fCaQ7HOyP0c9HhBg7OFO8N","tagline":null,"urlname":"/investor_page/triventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJHdj50LDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"fa6979a1-be2e-4d89-8b5e-d6adfb7eb460","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$dzsYbSrKJgvPvZBbbhpoltTv6B2WRBi4fCaQ7HOyP0c9HhBg7OFO8N","leadcaption":"","followupcaption":"Follow on "},{"name":"Diamond Bio Fund ","type":"Investor","amount":0,"hidden":false,"country":"Taiwan","fullurl":"/investor_page/diamond-bio-fund","logokey":"$RBmMZA7Nq3HCX8yiJgcmSVnzy04oqJK6CPrYOcDyWVNod5FRaUtaaM","tagline":"","urlname":"/investor_page/diamond-bio-fund","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODY5ZHzCAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"fd3dba57-9bfe-4024-98e8-9c84c7d172de","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$RBmMZA7Nq3HCX8yiJgcmSVnzy04oqJK6CPrYOcDyWVNod5FRaUtaaM","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":8000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODknp7yCww","date":"Apr 2015","amount":"$2.65M","source":"From Yishai Potack, their VP BD","eventtype":"FundingRoundEvent","investment":[{"name":"Docor International Management","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/docor","logokey":"$OfHtk8MQpXyjuEfISyRNC2I0FArnwi7SC4uowUIF3xWUco4YnAg2VW","tagline":null,"urlname":"/investor_page/docor","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMnYj5YKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"760c5633-31d8-43ec-92ac-fefbfc910c01","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$OfHtk8MQpXyjuEfISyRNC2I0FArnwi7SC4uowUIF3xWUco4YnAg2VW","leadcaption":"","followupcaption":""},{"name":"Office of the Chief Scientist","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"7dd77d93-3a7d-4caa-952a-6b0681aee191","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"8aaf98bf-7c6d-4796-ad30-9ec15e44ac29","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"","followupcaption":""},{"name":"Triventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/triventures","logokey":"$dzsYbSrKJgvPvZBbbhpoltTv6B2WRBi4fCaQ7HOyP0c9HhBg7OFO8N","tagline":null,"urlname":"/investor_page/triventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJHdj50LDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"8ede30b7-6058-49b8-8aa9-ae31d72bfe20","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$dzsYbSrKJgvPvZBbbhpoltTv6B2WRBi4fCaQ7HOyP0c9HhBg7OFO8N","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2650000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCko8SLCQw","date":"Jan 2010","amount":"$488K","source":"From Yishai Potack, their VP BD","eventtype":"FundingRoundEvent","investment":[{"name":"Sagam Group","type":"Other","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/sagam-group","logokey":null,"tagline":"","urlname":"/company_page/sagam-group","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC4jqa7CAw","fundingtype":"Other","leadpartner":null,"investmentid":"d4d17b5b-ad6c-4847-9735-3c7af0c0b0f8","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/startups-icon.svg","leadcaption":"","followupcaption":""},{"name":"VLX Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/vlx","logokey":"$dXu7ZEAH5LAowXCtVDAvI4T3opiaicfOFgluzyyEJuZioaeoMbfNc4","tagline":null,"urlname":"/investor_page/vlx","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgLHYycwJDA","fundingtype":"Incubator","leadpartner":null,"investmentid":"f2528523-6ebc-48d5-88f6-e49ecad9b280","fundingsubtype":"Incubator","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$dXu7ZEAH5LAowXCtVDAvI4T3opiaicfOFgluzyyEJuZioaeoMbfNc4","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":488000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"1/2010","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"EyeYon Medical","logourl":"https://storage.googleapis.com/clean-finder-353810/$i7qTnXujDHBFlWqOeU7FOBD1hNA4rhtNw6FLVjIMgJdr9rbbtJUquZ","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$i7qTnXujDHBFlWqOeU7FOBD1hNA4rhtNw6FLVjIMgJdr9rbbtJUquZ","seoabout":"EyeYon Medical is a start-up company specializing in developing medical ophthalmic devices for complications resulting from various corneal diseases, inclu...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":5,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"},{"depth":2,"name":"Implants","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeKhcYLDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA>Implants#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeKhcYLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA>Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA/Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA|2:>TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA/Implants#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeKhcYLDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Medical Devices","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices","children":[{"title":"Medical Treatment & Therapeutics","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices>Medical Treatment & Therapeutics"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Patients","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"},{"title":"Providers","key":"0-0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]}]}],"coreTechnology":[{"title":"Materials & Substances","key":"0-0","path":"TechnologyClassificationModel>Materials & Substances","children":[{"title":"Implants","key":"0-0-0","path":"TechnologyClassificationModel>Materials & Substances>Implants"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"},{"depth":2,"name":"Implants","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeKhcYLDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Medical Devices","Medical Treatment & Therapeutics"],"coreTechnology":["Materials & Substances","Implants"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Patients","Providers"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD7wsffCww","date":"Mar 2021","amount":"$25M","source":"https://www.calcalistech.com/ctech/articles/0,7340,L-3899001,00.html","eventtype":"FundingRoundEvent","investment":[{"name":"CR-CP Life Science Fund","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/cr-cp-life-science-fund","logokey":"$WdsFXZ0KSopNYQQT3Blpy40aG53OqLplEalxSZSCZoMggy3vYLKVC7","tagline":"","urlname":"/investor_page/cr-cp-life-science-fund","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCxhMbjCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"34392b68-c7bb-41c2-8383-136d1a1f2859","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$WdsFXZ0KSopNYQQT3Blpy40aG53OqLplEalxSZSCZoMggy3vYLKVC7","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"Triventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/triventures","logokey":"$dzsYbSrKJgvPvZBbbhpoltTv6B2WRBi4fCaQ7HOyP0c9HhBg7OFO8N","tagline":null,"urlname":"/investor_page/triventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJHdj50LDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"25dc8f5b-2e60-4373-86d1-1f25abea012d","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$dzsYbSrKJgvPvZBbbhpoltTv6B2WRBi4fCaQ7HOyP0c9HhBg7OFO8N","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"Quark Venture","type":"Investor","amount":0,"hidden":false,"country":"Canada","fullurl":"/investor_page/quark-venture","logokey":"$YqTloV7jHhFJJgexhl8uKOwKGRlphv3Hg6jIB4VrIT6PyOv9oLRWLH","tagline":"","urlname":"/investor_page/quark-venture","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCUwsWJCAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"2ed1b804-bcad-4bad-be9f-e506cfb4439f","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YqTloV7jHhFJJgexhl8uKOwKGRlphv3Hg6jIB4VrIT6PyOv9oLRWLH","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Diamond Bio Fund ","type":"Investor","amount":0,"hidden":false,"country":"Taiwan","fullurl":"/investor_page/diamond-bio-fund","logokey":"$RBmMZA7Nq3HCX8yiJgcmSVnzy04oqJK6CPrYOcDyWVNod5FRaUtaaM","tagline":"","urlname":"/investor_page/diamond-bio-fund","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODY5ZHzCAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"39f061d4-3959-42c2-982b-7e27624d8349","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$RBmMZA7Nq3HCX8yiJgcmSVnzy04oqJK6CPrYOcDyWVNod5FRaUtaaM","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"BPC","type":"Investor","amount":0,"hidden":false,"country":"Hong Kong","fullurl":"/investor_page/bpc","logokey":"$5LpX3UyIHnSCti51BHS7rHQYLbSUeAxsrE38k2XbGIWXglhasOpkEt","tagline":"","urlname":"/investor_page/bpc","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCb2IaFCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"9b27f373-1d49-4b7f-9708-c5530017a317","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$5LpX3UyIHnSCti51BHS7rHQYLbSUeAxsrE38k2XbGIWXglhasOpkEt","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"c08da446-12fe-4578-a2af-af9061ab76d3","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"Rimonci Capital","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/rimonci-capital-1","logokey":"$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","tagline":"","urlname":"/investor_page/rimonci-capital-1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCRwd68CAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"d342b8bc-0e54-41cb-84c0-9fc1e6729abe","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"C Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":25000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOC4jubUCww","date":"Mar 2017","amount":"$8M","source":"From Yishai Potack, their VP BD","eventtype":"FundingRoundEvent","investment":[{"name":"Rimonci Capital","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/rimonci-capital-1","logokey":"$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","tagline":"","urlname":"/investor_page/rimonci-capital-1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCRwd68CAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"9473bc17-35af-456d-a6a3-cd1ecbb3f912","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Y4rMkMN8HU694sMLMctTcGCncjbqJTyjPIvR8syIa3e2xz0qLo7ZhO","leadcaption":"","followupcaption":""},{"name":"Gauss Group","type":"Company","amount":0,"hidden":true,"country":"United States","fullurl":"/company_page/gauss-group","logokey":"$miV2PdhPZ9qkQhc613cswuVLhYjU9YgAdbyWqNVlXoaevIN5ordyKS","tagline":"Software Development and Data Science Consulting Services","urlname":"/company_page/gauss-group","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEvIy7CQw","fundingtype":"Company","leadpartner":null,"investmentid":"d38f45f6-5f8d-481e-abe9-a064dcf1b6ec","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$miV2PdhPZ9qkQhc613cswuVLhYjU9YgAdbyWqNVlXoaevIN5ordyKS","leadcaption":"","followupcaption":""},{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"ed858b52-091a-403e-a4ef-469e47188221","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"","followupcaption":"Follow on "},{"name":"Triventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/triventures","logokey":"$dzsYbSrKJgvPvZBbbhpoltTv6B2WRBi4fCaQ7HOyP0c9HhBg7OFO8N","tagline":null,"urlname":"/investor_page/triventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJHdj50LDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"fa6979a1-be2e-4d89-8b5e-d6adfb7eb460","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$dzsYbSrKJgvPvZBbbhpoltTv6B2WRBi4fCaQ7HOyP0c9HhBg7OFO8N","leadcaption":"","followupcaption":"Follow on "},{"name":"Diamond Bio Fund ","type":"Investor","amount":0,"hidden":false,"country":"Taiwan","fullurl":"/investor_page/diamond-bio-fund","logokey":"$RBmMZA7Nq3HCX8yiJgcmSVnzy04oqJK6CPrYOcDyWVNod5FRaUtaaM","tagline":"","urlname":"/investor_page/diamond-bio-fund","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODY5ZHzCAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"fd3dba57-9bfe-4024-98e8-9c84c7d172de","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$RBmMZA7Nq3HCX8yiJgcmSVnzy04oqJK6CPrYOcDyWVNod5FRaUtaaM","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":8000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODknp7yCww","date":"Apr 2015","amount":"$2.65M","source":"From Yishai Potack, their VP BD","eventtype":"FundingRoundEvent","investment":[{"name":"Docor International Management","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/docor","logokey":"$OfHtk8MQpXyjuEfISyRNC2I0FArnwi7SC4uowUIF3xWUco4YnAg2VW","tagline":null,"urlname":"/investor_page/docor","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMnYj5YKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"760c5633-31d8-43ec-92ac-fefbfc910c01","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$OfHtk8MQpXyjuEfISyRNC2I0FArnwi7SC4uowUIF3xWUco4YnAg2VW","leadcaption":"","followupcaption":""},{"name":"Office of the Chief Scientist","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"7dd77d93-3a7d-4caa-952a-6b0681aee191","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"8aaf98bf-7c6d-4796-ad30-9ec15e44ac29","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"","followupcaption":""},{"name":"Triventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/triventures","logokey":"$dzsYbSrKJgvPvZBbbhpoltTv6B2WRBi4fCaQ7HOyP0c9HhBg7OFO8N","tagline":null,"urlname":"/investor_page/triventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJHdj50LDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"8ede30b7-6058-49b8-8aa9-ae31d72bfe20","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$dzsYbSrKJgvPvZBbbhpoltTv6B2WRBi4fCaQ7HOyP0c9HhBg7OFO8N","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2650000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCko8SLCQw","date":"Jan 2010","amount":"$488K","source":"From Yishai Potack, their VP BD","eventtype":"FundingRoundEvent","investment":[{"name":"Sagam Group","type":"Other","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/sagam-group","logokey":null,"tagline":"","urlname":"/company_page/sagam-group","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC4jqa7CAw","fundingtype":"Other","leadpartner":null,"investmentid":"d4d17b5b-ad6c-4847-9735-3c7af0c0b0f8","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/startups-icon.svg","leadcaption":"","followupcaption":""},{"name":"VLX Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/vlx","logokey":"$dXu7ZEAH5LAowXCtVDAvI4T3opiaicfOFgluzyyEJuZioaeoMbfNc4","tagline":null,"urlname":"/investor_page/vlx","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgLHYycwJDA","fundingtype":"Incubator","leadpartner":null,"investmentid":"f2528523-6ebc-48d5-88f6-e49ecad9b280","fundingsubtype":"Incubator","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$dXu7ZEAH5LAowXCtVDAvI4T3opiaicfOFgluzyyEJuZioaeoMbfNc4","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":488000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}